The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
24 Feb 2024
24 Feb 2024
Historique:
received:
10
07
2023
accepted:
09
02
2024
medline:
25
2
2024
pubmed:
25
2
2024
entrez:
24
2
2024
Statut:
epublish
Résumé
The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that modelling of intermittent ceralasertib treatment in mouse tumor models reveals CD8
Identifiants
pubmed: 38402224
doi: 10.1038/s41467-024-45996-4
pii: 10.1038/s41467-024-45996-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1700Informations de copyright
© 2024. The Author(s).
Références
Forment, J. V. & O’Connor, M. J. Targeting the replication stress response in cancer. Pharm. Ther. 188, 155–167 (2018).
doi: 10.1016/j.pharmthera.2018.03.005
Dillon, M. T. et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. Clin. Cancer Res. 25, 3392–3403 (2019).
pubmed: 30770349
pmcid: 6551222
doi: 10.1158/1078-0432.CCR-18-1821
Feng, X. et al. ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways. EMBO J. 39, e104036 (2020).
pubmed: 32484965
pmcid: 7361286
doi: 10.15252/embj.2019104036
Sheng, H. et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J. Immunother. Cancer 8, e000340 (2020).
pubmed: 32461345
pmcid: 7254123
doi: 10.1136/jitc-2019-000340
Vendetti, F. P. et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J. Clin. Invest 128, 3926–3940 (2018).
pubmed: 29952768
pmcid: 6118586
doi: 10.1172/JCI96519
Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J. Natl. Cancer Inst. 109, djw199 (2017).
pubmed: 27707838
doi: 10.1093/jnci/djw199
Sato, H. et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat. Commun. 8, 1751 (2017).
pubmed: 29170499
pmcid: 5701012
doi: 10.1038/s41467-017-01883-9
Sun, L. L. et al. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am. J. Cancer Res. 8, 1307–1316 (2018).
pubmed: 30094103
pmcid: 6079156
McGrail, D. J. et al. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci. Transl. Med. 13, eabe6201 (2021).
pubmed: 34705519
pmcid: 8577990
doi: 10.1126/scitranslmed.abe6201
Foote, K. M. et al. Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) Kinase with application as an anticancer agent. J. Med. Chem. 61, 9889–9907 (2018).
pubmed: 30346772
doi: 10.1021/acs.jmedchem.8b01187
Wilson, Z. et al. ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res. 82, 1140–1152 (2022).
pubmed: 35078817
pmcid: 9359726
doi: 10.1158/0008-5472.CAN-21-2997
Besse, B., et al. OA15.05—HUDSON: An open-label, multi-drug, biomarker-directed phase 2 study in NSCLC patients who progressed on anti-PD-(L)1 therapy. J. Thoracic Oncol. 17, S41–S42 (2022).
Besse, B., et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat. Med. https://doi.org/10.1038/s41591-024-02808-y (2024 Online ahead of print.
Kim, R. et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann. Oncol. 33, 193–203 (2022).
pubmed: 34710570
doi: 10.1016/j.annonc.2021.10.009
Kwon, M. et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J. Immunother. Cancer 10, e005041 (2022).
pubmed: 35790315
pmcid: 9258491
doi: 10.1136/jitc-2022-005041
Hernandez, M. et al. P16.07 immuno-modulatory effects of ceralasertib in combination with durvalumab in NSCLC with progression on anti-PD(L)1 treatment (HUDSON). J. Thorac. Oncol. 16, S350–S351 (2021).
doi: 10.1016/j.jtho.2021.01.553
Iyer, S. et al. Abstract CT039: immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617). Cancer Res. 83, CT039–CT039 (2023).
doi: 10.1158/1538-7445.AM2023-CT039
Young, L. A. et al. Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress. Cancer Res. 79, 3762–3775 (2019).
pubmed: 31123088
doi: 10.1158/0008-5472.CAN-18-2480
Lloyd, R. L. et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 39, 4869–4883 (2020).
pubmed: 32444694
pmcid: 7299845
doi: 10.1038/s41388-020-1328-y
Lopez-Pelaez, M. et al. Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation. Oncoimmunology 11, 2117321 (2022).
pubmed: 36117525
pmcid: 9481087
doi: 10.1080/2162402X.2022.2117321
Kumar, K. G., Krolewski, J. J. & Fuchs, S. Y. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J. Biol. Chem. 279, 46614–46620 (2004).
pubmed: 15337770
doi: 10.1074/jbc.M407082200
Kumar, K. G. et al. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 22, 5480–5490 (2003).
pubmed: 14532120
doi: 10.1093/emboj/cdg524
Bhattacharya, S. et al. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol. Med. 6, 384–397 (2014).
pubmed: 24480543
pmcid: 3958312
doi: 10.1002/emmm.201303236
Bradley, K. C. et al. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell Rep. 28, 245–256 e244 (2019).
pubmed: 31269444
doi: 10.1016/j.celrep.2019.05.105
Ardanuy, J., Scanlon, K., Skerry, C., Fuchs, S. Y. & Carbonetti, N. H. Age-dependent effects of type I and Type III IFNs in the pathogenesis of Bordetella pertussis infection and disease. J. Immunol. 204, 2192–2202 (2020).
pubmed: 32152071
doi: 10.4049/jimmunol.1900912
Zhang, H. et al. Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nat. Cancer 3, 808–820 (2022).
pubmed: 35637402
pmcid: 9339499
doi: 10.1038/s43018-022-00383-0
Lundin, A. et al. Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery. Nat. Commun. 11, 4903 (2020).
pubmed: 32994412
pmcid: 7525522
doi: 10.1038/s41467-020-18548-9
Veglia, F. & Gabrilovich, D. I. Dendritic cells in cancer: the role revisited. Curr. Opin. Immunol. 45, 43–51 (2017).
pubmed: 28192720
pmcid: 5449252
doi: 10.1016/j.coi.2017.01.002
Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485–498 (2021).
pubmed: 33526920
pmcid: 7849958
doi: 10.1038/s41577-020-00490-y
Alicea-Torres, K. et al. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat. Commun. 12, 1717 (2021).
pubmed: 33741967
pmcid: 7979850
doi: 10.1038/s41467-021-22033-2
Vendetti, F. P. et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight 8, e165615 (2023).
pubmed: 36810257
pmcid: 9977511
doi: 10.1172/jci.insight.165615
Sugitani, N. et al. Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-alpha/beta expression. Cell Rep. 40, 111371 (2022).
pubmed: 36130512
pmcid: 9646445
doi: 10.1016/j.celrep.2022.111371
Staniszewska, A. D. et al. PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. Oncoimmunology 11, 2083755 (2022).
pubmed: 35756843
pmcid: 9225208
doi: 10.1080/2162402X.2022.2083755
Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722–737 (2019).
pubmed: 31015319
pmcid: 6548644
doi: 10.1158/2159-8290.CD-18-1218
Sen, T. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 9, 646–661 (2019).
pubmed: 30777870
pmcid: 6563834
doi: 10.1158/2159-8290.CD-18-1020
Hather, G. et al. Growth rate analysis and efficient experimental design for tumor xenograft studies. Cancer Inf. 13, 65–72 (2014).
Sanseviero, E., Kim, R. & Gabrilovich, D. I. Isolation and phenotyping of splenic myeloid-derived suppressor cells in murine cancer models. Methods Mol. Biol. 2236, 19–28 (2021).
pubmed: 33237537
doi: 10.1007/978-1-0716-1060-2_3
Veglia, F. et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat. Commun. 8, 2122 (2017).
pubmed: 29242535
pmcid: 5730553
doi: 10.1038/s41467-017-02186-9
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
pubmed: 19910308
doi: 10.1093/bioinformatics/btp616
Kasprzyk, A. BioMart: driving a paradigm change in biological data management. Database (Oxford) 2011, bar049 (2011).
pubmed: 22083790
doi: 10.1093/database/bar049
Han, G., Spitzer, M. H., Bendall, S. C., Fantl, W. J. & Nolan, G. P. Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry. Nat. Protoc. 13, 2121–2148 (2018).
pubmed: 30258176
pmcid: 7075473
doi: 10.1038/s41596-018-0016-7
Chevrier, S. et al. Compensation of signal spillover in suspension and imaging mass cytometry. Cell Syst. 6, 612–620 e615 (2018).
pubmed: 29605184
pmcid: 5981006
doi: 10.1016/j.cels.2018.02.010
Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytom. A J. Int. Soc. Anal. Cytol. 87, 636–645 (2015).
doi: 10.1002/cyto.a.22625
Cribari-Neto, F. & Zeileis, A. Beta regression in R. J. Stat. Softw. 34, 1–24 (2010).
doi: 10.18637/jss.v034.i02